Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share (the "Common Stock")
-
Shares outstanding
-
62,650,155
-
Total 13F shares
-
56,110,184
-
Share change
-
-2,942,453
-
Total reported value
-
$1,215,929,511
-
Put/Call ratio
-
60%
-
Price per share
-
$21.67
-
Number of holders
-
196
-
Value change
-
-$60,792,173
-
Number of buys
-
73
-
Number of sells
-
107
Institutional Holders of Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) as of Q4 2023
As of 31 Dec 2023,
Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) was held by
196 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
56,110,184 shares.
The largest 10 holders included
WELLINGTON MANAGEMENT GROUP LLP, FMR LLC, VANGUARD GROUP INC, RTW INVESTMENTS, LP, BlackRock Inc., STATE STREET CORP, Bellevue Group AG, JPMORGAN CHASE & CO, COWEN AND COMPANY, LLC, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
196
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.